argenx

argenx FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of argenx (ARGX.BR) as of Nov 17, 2026 is 65.35 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -18.13 % — a change of -460.39% (higher).

FCF Conversion

65.35 %

YoY

-460.39%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of argenx is 2025 65.35 % . FCF Conversion Rate (FCF/EBITDA) of argenx was 2024 -18.13 % . It decreases by -460.39% higher compared to the previous year.

The argenx FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
81.82 USD
Jan 1, 2019
-57.89 USD
Jan 1, 2020
66.33 USD
Jan 1, 2021
178.38 USD
Jan 1, 2022
136.22 USD
Jan 1, 2023
157.31 USD
Jan 1, 2024
-18.13 USD
Jan 1, 2025
65.35 USD
The argenx FCF Conversion history
YEARFCF ConversionYoY
65.35 %-460.39%
-18.13 %-111.53%
157.31 %+15.48%
136.22 %-23.63%
178.38 %+168.91%
66.33 %-214.59%
-57.89 %-170.75%
81.82 %-37.74%
131.42 %-388.46%
-45.56 %-149.21%
92.58 %+76.17%
52.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

argenx Stock analysis

What does argenx do? Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. The company was founded in 2008 and is headquartered in Gent, Belgium. Argenx utilizes an innovative technology platform, the Simple Antibody platform, to develop customized antibodies with high efficacy. Argenx operates in two main business areas: clinical development and licensing. The company aims to produce outstanding therapeutic agents from each of its platform technologies and drug candidates, which can be used as antibody therapies against serious autoimmune diseases or cancer. Argenx's main product is the drug Efgartigimod, a monoclonal antibody developed for the treatment of multiple autoimmune diseases, particularly generalized Myasthenia Gravis (GMG). The drug is currently in clinical development. In recent years, Argenx has made significant progress in the development of new drugs. For example, the company has announced the discovery of new antibodies for the treatment of Myasthenia Gravis, rheumatoid arthritis, and various types of cancer. Licensing these development pipelines opens up new opportunities for Argenx to create additional therapy options for patients with serious illnesses. Argenx has also established partnerships with leading pharmaceutical companies such as Shire and AbbVie to expand its technology platform and drug candidates into new areas of application. The company is currently working on the development of therapies for rare and serious diseases that have no satisfactory treatment options. With the advancement of its innovative technology platform and the expansion of its portfolio of drug candidates, Argenx is on a promising path to play a leading role in the industry. The company is building an extensive network of partnerships and collaborations to accelerate the further development of its technology platform and products, and to achieve further success in the search for new therapeutic applications and areas of application. Looking ahead, Argenx is poised to play a significant role in the biopharmaceutical industry, particularly in the development of personalized therapy options for the treatment of serious diseases where no satisfactory treatment options currently exist. Argenx is proud of its dedicated team of employees who strive every day to realize the company's vision - to help patients cope with serious illnesses through new and innovative therapies. Output: Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. argenx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about argenx stock

FCF Conversion Rate (FCF/EBITDA) of argenx is 65.35 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of argenx changed from -18.13 % to 65.35 %, representing a -460.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) argenx since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s argenx with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — argenx

All Key Metrics — argenx